Latest News & Features
Asia-Pacific
The Australian health minister has revealed a series of reforms that will aim to reduce spending on patented drugs from the pharmaceutical industry. 27 May 2015
Americas
A US appeals court has issued a mixed judgment in a patent dispute that saw Novartis file infringement claims against both Watson Pharmaceuticals and Par Pharmaceutical. 26 May 2015
Big Pharma
Teva has successfully defended two patents related to its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate) at the English High Court. 22 May 2015
Asia-Pacific
February’s amendments to the Australian IP Act seek to increase the effectiveness and efficiency of the country’s IP system. LSIPR takes a look at the major changes and considers who will benefit most in the life sciences sector. 21 May 2015
Americas
Gilead Sciences is facing a challenge to its attempt to obtain a patent for its hepatitis C drug Sovaldi in certain Asian, Latin American and European countries. 20 May 2015
Americas
Californian genetic analysis company Illumina has sued Ariosa Diagnostics for allegedly infringing a patent through its Harmony Prenatal Test. 19 May 2015
Americas
The US Court of Appeals for the Federal Circuit has vacated and remanded a case between Classen Immunotherapies and Elan Pharmaceuticals, to determine whether Elan infringed a Classen patent when it tried to change the product label for one of its drugs. 18 May 2015
Asia
The Supreme Court of India has ordered Glenmark Pharmaceuticals to stop making generic versions of Merck Sharp & Dohme’s diabetes drugs Januvia and Janumet. 18 May 2015
Americas
The University of Oxford has today launched a £300 million project aimed at enhancing the intellectual property of businesses active in the life sciences and medicinal sciences industries. 14 May 2015
Americas
The ability of third parties to participate in patent challenges has led to new dynamics, including the possibility of parties profiting from movements in stock price and the prospect of patent oppositions by not-for-profit proxies, as Marc Cavan and Phillip Kurs of law firm Ropes & Gray describe. 14 May 2015